BioCentury
ARTICLE | Clinical News

RP5063: Completed Phase II enrollment

January 21, 2013 8:00 AM UTC

Reviva completed enrollment of 234 schizophrenia patients in the double-blind, placebo-controlled, international Phase II REFRESH trial comparing 15, 30 or 50 mg daily RP5063 vs. 15 mg daily aripipraz...